FDA Investigator

Kara A Scheibner

Latest inspection on record: Navi Mumbai, India, April 2026 · records back to 2017

Human Drugs

FDA inspection record · Last updated July 12, 2026

Overview

  • 35 inspections across 31 sites are on record.
  • 9 Form 483 observations are attributed to this investigator.
  • Most recent recorded activity is 2026-04-23.

At a glance

Inspections

35

Sites

31

Observations

9

Career since

Jan 2017

Recent inspections

Most recent inspections in the published record.

SiteDateCategoryForm 483
Sitec Labs Limited23 Apr 2026Human DrugsOn file
Cliantha Research Limited17 Apr 2026Human DrugsOn file
Frontage Laboratories Shanghai Co., Ltd.5 Feb 2026Human Drugs
Labcorp Drug Development30 Jan 2026Human Drugs
Amphastar Pharmaceuticals, Inc.7 Nov 2025Human DrugsOn file

Sites inspected

Sitec Labs LimitedNavi Mumbai, India1 insp.
Cliantha Research LimitedAhmedabad, India1 insp.
Labcorp Drug DevelopmentShanghai, China1 insp.
Amphastar Pharmaceuticals, Inc.Rancho Cucamonga, United States1 insp.

Co-investigators

Investigators who share inspections with this person.

Amanda Lewin4 shared
Xiaohan Cai2 shared
Xingfang Li1 shared
Koffi A Amegadje1 shared

Full investigator report

Get the verbatim findings behind Kara A Scheibner's 9 observations

Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.

  • New inspections and Form 483s, mapped to the CFR citation
  • Warning letter outcomes, and the citation patterns they repeat
  • Their co-investigators, so no surprises about who shows up on site